


What is Claimed is:

1. A pharmaceutical composition useful for the treatment or prophylaxis of viral infections comprising nevirapine and
5 at least one antiviral active compound of formula (I)



wherein said Base is selected from the group consisting of: thymine, cytosine, adenine, guanine, inosine, uracil,
10 5-ethyluracil and 2,6-diaminopurine, or a pharmaceutically acceptable salt or prodrug thereof.

2. The pharmaceutical composition according to claim 1 wherein the compound of formula (I) is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or
15 prodrug thereof.
3. The pharmaceutical composition according to claim 1 wherein the compound of formula (I) is 2',3'-dideoxy-3'-fluoroguanosine (FLG) or a pharmaceutically acceptable salt or prodrug thereof.
20
4. The pharmaceutical composition according to claim 1 wherein the compound of formula (I) is 3'-deoxy-3'-fluoro-
25 5-O-[2-(L-valyloxy)-propionyl]guanosine or a pharmaceutically acceptable salt thereof.

5. The pharmaceutical composition according to claim 1
wherein nevirapine and the compound of formula (I) are
present in a synergistic ratio.
- 5 6. The pharmaceutical composition according to claim 1
wherein nevirapine and the compound of formula (I) are
present in a ratio between about 1:250 to about 250:1.
- 10 7. The pharmaceutical composition according to claim 6
wherein nevirapine and the compound of formula (I), are
present in a ratio between about 1:50 to about 50:1.
- 15 8. The pharmaceutical composition according to claim 1
further comprising a further nucleoside reverse
transcriptase (NRTI), or a pharmaceutically acceptable
salt or prodrug thereof.
- 20 9. The pharmaceutical composition according to claim 1
further comprising at least one pharmaceutically
acceptable carrier.
10. The pharmaceutical composition according to claim 1
further comprising a protease inhibitor.
- 25 11. The pharmaceutical composition according to claim 1
further comprising an entry inhibitor.
- 30 12. The pharmaceutical composition according to claim 10
further comprising an entry inhibitor.
- 35 13. The pharmaceutical composition according to claim 10
further comprising an integrase inhibitor.
14. The pharmaceutical composition according to claim 10
further comprising a further nucleoside reverse

transcriptase (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

15. The pharmaceutical composition according to claim 11
5 further comprising a further nucleoside reverse transcriptase (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.


16. The pharmaceutical composition according to claim 12
10 further comprising a further nucleoside reverse transcriptase (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

17. The pharmaceutical composition according to claim 13
15 further comprising a further nucleoside reverse transcriptase (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

18. The pharmaceutical composition according to claim 1
20 further comprising a maturation inhibitor or an antisense compound.

19. The pharmaceutical composition according to claim 1
further comprising an antiviral agent selected from the
25 group consisting of: PA-457, KPC-2, HGTB-43,
delavirdine, efavirenz, (+)- calanolide A and B,
capravirine, GW-695634, MIV-150, MV026048, NV-05, R-
278474, RS-1588, TMC-120/125, TMC-125, UC-781, and YM-
215389.

30
20. A method for the prophylaxis or treatment of a viral
infection in a patient comprising administering
nevirapine in combination or alternation with at least
one antiviral active compound of formula (I)



wherein Base is selected from the group consisting of thymine, cytosine, adenine, guanine, inosine, uracil, 5-ethyluracil and 2,6-diaminopurine, or a pharmaceutically acceptable salt or prodrug thereof.

- 5 21. The method according to claim 20, wherein the compound of formula (I) is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.
- 10 22. The method according to claim 20, wherein the compound of formula (I) is 2',3'-dideoxy-3'-fluoroguanosine (FLG), or a pharmaceutically acceptable salt or prodrug thereof.
- 15 23. The method according to claim 20, wherein the compound of formula (I) is 3'-deoxy-3'-fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine or a pharmaceutically acceptable salt thereof.
- 20 24. The method according to claim 20, wherein the viral infection is a human retroviral infection (HRV).
- 25 25. The method according to claim 24, wherein the human retroviral infection is a multiresistant human immunodeficiency virus (HIV) infection.
- 26. The method according to claim 24, wherein perinatal transmission of the human retroviral infection (HRV) from mother to baby is prevented.

27. The method according to claim 20, wherein nevirapine and
the compound of formula (I) are administered to the
patient in combination or alternation in a synergistic
ratio.
- 5
28. The method according to claim 20, wherein nevirapine and
the compound of formula (I) are administered to the
patient in combination or alternation in a ratio between
about 1:250 to about 250:1.
- 10
29. The method according to claim 28, wherein nevirapine and
the at least one compound of formula (I) are administered
to the patient in combination or alternation in a ratio
between about 1:50 to about 50:1.
- 15
30. The method according to claim 20, further comprising
administering in combination or alternation a further
nucleoside reverse transcriptase inhibitor (NRTI), or a
pharmaceutically acceptable salt or prodrug thereof.
- 20
31. The method according to claim 20 further comprising
administering a protease inhibitor.
- 25
32. The method according to claim 20 further comprising
administering an entry inhibitor.
- 30
33. The method according to claim 31 further comprising
administering an entry inhibitor.
34. The method according to claim 31 further comprising
administering an integrase inhibitor.
- 35
35. The method according to claim 31 further comprising
administering a further nucleoside reverse transcriptase


inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

36. The method according claim 32 further comprising
5 administering a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

37. The method according claim 33 further comprising
10 administering a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

38. The method according claim 34 further comprising
15 administering a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

39. A kit of parts for the prophylaxis or treatment of a
20 viral infection in a patient, comprising
(a) a first containment containing a pharmaceutical composition comprising nevirapine and at least one pharmaceutically acceptable carrier, and
(b) a second containment containing a pharmaceutical composition comprising an antiviral active compound
25 of formula (I)



I

wherein Base is selected from the group consisting of thymine, cytosine, adenine, guanine, inosine, uracil, 5-ethyluracil and 2,6-diaminopurine, or a pharmaceutically acceptable salt or prodrug thereof, and at least one
5 pharmaceutically acceptable carrier.

40. The kit of parts according to claim 39, wherein the compound of formula (I) is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.

10

41. The kit of parts according to claim 39, wherein the compound of the formula (I) is 2',3'-dideoxy-3'-fluoroguanosine (FLG), or a pharmaceutically acceptable salt or prodrug thereof.

15

42. The kit of parts according to claim 39, wherein the compound of the formula (I) is 3'-deoxy-3'-fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine or a pharmaceutically acceptable salt thereof.

20

43. The kit of parts according to claim 39 further comprising a containment containing a pharmaceutical composition comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

25

44. The kit of parts according to claim 39 further comprising a containment containing a pharmaceutical composition comprising a protease inhibitor.

30

45. The kit of parts according to claim 39 further comprising a containment containing a pharmaceutical composition comprising an entry inhibitor.

46. The kit of parts according to claim 44 further comprising
a containment containing a pharmaceutical composition
comprising an entry inhibitor.
- 5 47. The kit of parts according to claim 44 further comprising
a containment containing a pharmaceutical composition
comprising an integrase inhibitor.
- 10 48. The kit of parts according to claim 44 further comprising
a containment containing a pharmaceutical composition
comprising a further nucleoside reverse transcriptase
inhibitor (NRTI), or a pharmaceutically acceptable salt
or prodrug thereof.
- 15 49. The kit of parts according to claim 45 further comprising
a containment containing a pharmaceutical composition
comprising a further nucleoside reverse transcriptase
inhibitor (NRTI), or a pharmaceutically acceptable salt
or prodrug thereof.
- 20 50. The kit of parts according to claim 46 further comprising
a containment containing a pharmaceutical composition
comprising a further NRTI, or a pharmaceutically
acceptable salt or prodrug thereof.
- 25 51. The kit of parts according to claim 47 further comprising
a containment containing a pharmaceutical composition
comprising a further nucleoside reverse transcriptase
inhibitor (NRTI), or a pharmaceutically acceptable salt
30 or prodrug thereof.